fda compounding semaglutide crackdown news today 2025 US signals on compounded weight-loss drugs; Hims shares tumble Report: FDA must enforce rules

In 2018, there were fewer than five GLP-1 prescriptions per 10,000 women after giving birth

Publication Details Paper Title: Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation | Authors: Huilin Tang, Bingyu Zhang, Yiwen Lu, Dazheng Zhang, Ruishan Liu, Yuan Lu, George Cotsarelis, David A

This hyperphagia likely contributes to the massive increase in body fat, where the amount of fat detected in both fat depots examined (IWAT and GWAT) doubled in males and tripled in younger females

GLP-1 Lawsuits: Summary of Key Information Ozempic/GLP-1 Injury Lawsuit Complaints More than a thousand individuals who have taken GLP-1 receptor agonist medications (such as Ozempic, Mounjaro, Wegovy, and Rybelsus) to treat diabetes and/or obesity have filed lawsuits seeking to recover money damages for injuries they claim to have suffered as a result of their using the diabetes and/or weight loss drugs

% Daily Value (DV) in 1 Serving